Last reviewed · How we verify
HEC585 dose B
At a glance
| Generic name | HEC585 dose B |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase ll Study of HEC585 in Patients With IPF (PHASE2)
- A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEC585 dose B CI brief — competitive landscape report
- HEC585 dose B updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI